The FDA’s new draft guidance on shared risk evaluation and mitigation strategies (REMS) does little to stop branded drug companies from using REMS to delay generic competition.
The Food and Drug Administration sometimes imposes a REMS on a drug to ensure its benefits outweigh its risks. Ameet Sarpatwari, an instructor at Harvard Medical School, told me the draft guidance “is a helpful step in terms of improving efficiency,” but it doesn’t tackle how brand-name companies are able to use the requirement for a shared REMS to delay generic drugs.
Branded and generic manufacturers of the same product are required to reach agreement on a single, shared REMS system rather than implementing separate REMS. However, branded drug companies sometimes extend these negotiations as a way to slow generic competitors from reaching the market.
The draft guidance describes how branded-drug and generic companies can use a single electronic drug master file for submitting a shared REMS. This is intended to streamline the submission and review process for shared REMS systems. The new process would eliminate duplicative paperwork for sponsors, and would decrease the volume of forms the FDA’s reviewers must access, Food and Drug Administration Commissioner Scott Gottlieb said in an announcement.
Sarpatwari said branded drug companies use a couple of different strategies associated with REMS to delay generics.
One is the branded drug company delays generic entry through the shared REMS requirement. Another is that companies use REMS to delay generic drug launches by refusing to provide generic companies with drug samples needed for bioequivalence testing, Sarpatwari said.
Deborah Shelton, a pharmaceutical law attorney, told me the draft guidance “is not likely to have a significant effect on resolving issues of use of REMS to impede generic and biosimilars access” to branded drug samples. Biosimilars are less expensive versions of biologic drugs.
Shelton is with McCarter & English in Washington, and a Bloomberg Law advisory board member.
Read my full article here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)